AstraZeneca (AZN LN) announces results from the Phase III SERENA-6 trial showed camizestrant plus a cyclin-dependent kinase 4/6 inhibitor - palbociclib, ribociclib or abemaciclib - maintained its progression-free survival benefit
#UNITED KINGDOM#EUROPE#ASTRAZENECA PLC#AZN.LN#3I GROUP PLC#EQUITIES#EU SESSION#US SESSION#PHARMACEUTICALS#ASSET MANAGEMENT & CUSTODY BANKS#PHARMACEUTICALS (GROUP)#CAPITAL MARKETS#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#FINANCIAL SERVICES#FTSE 100 INDEX#III#FTSE 100